Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 17/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183770 | 0.91 | MAP4K4 (0.62) | IRAK4MAP4K4USP2ALDH1A1LMNA | |
| SCHEMBL4167322 | 0.90 | MAP4K4 (0.61) | IRAK4MAP4K4USP2ALDH1A1LMNA | |
| SCHEMBL4185474 | 0.88 | MAP4K4 (0.62) | IRAK4MAP4K4USP2ALDH1A1LMNA | |
| SCHEMBL4185148 | 0.88 | MAP4K4 (0.65) | IRAK4MAP4K4USP2ALDH1A1LMNA | |
| SCHEMBL4174267 | 0.83 | MAP4K4 (0.64) | IRAK4MAP4K4USP2ALDH1A1LMNA | |
| SCHEMBL4180117 | 0.82 | MAP4K4 (0.57) | IRAK4MAP4K4USP2ALDH1A1LMNA | |
| SCHEMBL4183733 | 0.81 | MAP4K4 (0.60) | IRAK4MAP4K4USP2ALDH1A1LMNA | |
| SCHEMBL4180220 | 0.81 | MAP4K4 (0.60) | IRAK4MAP4K4USP2ALDH1A1LMNA | |
| SCHEMBL4188018 | 0.81 | MAP4K4 (0.69) | IRAK4MAP4K4USP2ALDH1A1LMNA | |
| SCHEMBL4173751 | 0.80 | MAP4K4 (0.67) | IRAK4MAP4K4USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | IRAK4 864/4885MAP4K4 1662/4885CSF1R 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.